Skip to main content
. 2017 May 28;2017:7896160. doi: 10.1155/2017/7896160

Table 1.

Result of network meta-analysis.

Mean SD MC_error val2.5pc Median val97.5pc Intervention
d[2] −0.8045 2.202 0.0506 −4.705 −1.068 4.443 MSLZ 4 g/d
d[3] −1.053 1.715 0.03574 −4.16 −1.201 3.03 MSLZ 2-3/d
d[4] −1.389 2.222 0.0498 −5.236 −1.628 3.899 AZA
d[5] −0.4136 1.244 0.007319 −3.051 −0.406 2.152 BDND
d[6] −5.475 2.222 0.04268 −10.47 −5.287 −1.632 IFX (0/2/6/E8W)
d[7] −7.273 2.849 0.06321 −13.84 −6.948 −2.585 ADA 160/80/40
d[8] −0.05878 2.438 0.03836 −4.637 −0.2134 5.522 Untreated
d[9] −1.174 2.47 0.05239 −5.73 −1.367 4.581 TW
d[10] 1.062 1.848 0.01396 −2.81 1.075 4.86 LGG
d[11] −3.795 2.943 0.05731 −9.191 −4.021 3.016 MSLZ (2-3 g) + IFX (5 mg/kg, E8W)
d[12] −1.818 1.757 0.01178 −5.519 −1.814 1.87 ONDZ

Untreated, blank control group; MSLZ: mesalazine; BDND: budesonide; AZA: azathioprine; IFX: infliximab; ADA: adalimumab; TW: Tripterygium wilfordii; LGG: Lactobacillus GG; d[2] indicates the log odds ratio between treatment 2 and treatment 1 (d[1]); d[3] indicates the log odds ratio between treatment 3 and treatment 1 and so on.